NCT00621725View on ClinicalTrials.gov

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

January 31, 2014

Conditions

Advanced CancerHepatic Impairment

Interventions

DRUG

AZD2171

Oral dose

Trial Locations (3)

Unknown

Research Site, København Ø

Research Site, Nijmegen

Research Site, Rotterdam

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY